| scholarly article | Q13442814 |
| P2093 | author name string | Baltimore D | |
| Rice SA | |||
| Nabel GJ | |||
| Knipe DM | |||
| P433 | issue | 4845 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1299-1302 | |
| P577 | publication date | 1988-03-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells | |
| P478 | volume | 239 |
| Q33229419 | "UnPAKing" human immunodeficiency virus (HIV) replication: using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection |
| Q37280765 | 15-Deoxy-Delta12,14-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification. |
| Q44846323 | 5-Aza-cytosine derivative chemotherapy in AIDS. |
| Q40064469 | A 10-base-pair element of the human immunodeficiency virus type 1 long terminal repeat (LTR) is an absolute requirement for transactivation by the human cytomegalovirus 72-kilodalton IE1 protein but can be compensated for by other LTR regions in tra |
| Q24684723 | A Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoter |
| Q40106141 | A cellular function can enhance gene expression and plating efficiency of a mutant defective in the gene for ICP0, a transactivating protein of herpes simplex virus type 1 |
| Q34059393 | A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. |
| Q33616554 | A review on antibacterial, antiviral, and antifungal activity of curcumin |
| Q33662926 | A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat |
| Q59073190 | Activation of HIV gene expression during monocyte differentiation by induction of NF-kB |
| Q40603313 | Activation of HIV-1 transcription by Tat in cells derived from the CNS: evidence for the participation of NF-kappa B--a review |
| Q34193240 | Activation of human monocyte--derived macrophages with lipopolysaccharide decreases human immunodeficiency virus replication in vitro at the level of gene expression |
| Q36881679 | Activation of the human immunodeficiency virus long terminal repeat by herpes simplex virus type 1 is associated with induction of a nuclear factor that binds to the NF-kappa B/core enhancer sequence |
| Q40037740 | Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. |
| Q33930958 | Activation of the human immunodeficiency virus type 1 long terminal repeat by vaccinia virus |
| Q24682560 | Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1 |
| Q35231548 | Adenoviruses in the immunocompromised host |
| Q39559552 | Advances in human retroviruses |
| Q41688788 | An in vitro transcription analysis of early responses of the human immunodeficiency virus type 1 long terminal repeat to different transcriptional activators |
| Q45856643 | Analysis of the human immunodeficiency virus long terminal repeat by in vitro transcription competition and linker scanning mutagenesis |
| Q35871672 | Attenuation of DNA-dependent protein kinase activity and its catalytic subunit by the herpes simplex virus type 1 transactivator ICP0. |
| Q33834125 | Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis |
| Q36796481 | CD4-independent infection by human immunodeficiency virus type 1 after phenotypic mixing with human T-cell leukemia viruses |
| Q39900059 | Cell type-specific induction and inhibition of apoptosis by Herpes Simplex virus type 2 ICP10. |
| Q34647412 | Cellular stress rather than stage of the cell cycle enhances the replication and plating efficiencies of herpes simplex virus type 1 ICP0- viruses |
| Q36634412 | Central nervous system-derived cells express a kappa B-binding activity that enhances human immunodeficiency virus type 1 transcription in vitro and facilitates TAR-independent transactivation by Tat. |
| Q37080840 | Chromatin control of herpes simplex virus lytic and latent infection |
| Q38205291 | Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection |
| Q33950811 | Community respiratory viruses in individuals with human immunodeficiency virus infection |
| Q35870516 | Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site. |
| Q36686931 | Cooperative inhibition of NF-kappa B and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat |
| Q36633412 | Cooperativity among herpes simplex virus type 1 immediate-early regulatory proteins: ICP4 and ICP27 affect the intracellular localization of ICP0 |
| Q35174403 | Correlations Between theIn VitroandIn VivoActivity of Anti-HIV Agents: Implications for Future Drug Deyelopment |
| Q36954574 | Cytokine regulation of human immunodeficiency virus expression |
| Q36807977 | Cytomegalovirus activates transcription directed by the long terminal repeat of human immunodeficiency virus type 1. |
| Q40115449 | DNA binding by the herpes simplex virus type 1 ICP4 protein is necessary for efficient down regulation of the ICP0 promoter. |
| Q33784841 | Development of a self-inactivating lentivirus vector. |
| Q36781432 | Differences in activities of murine retroviral long terminal repeats in cytotoxic T lymphocytes and T-lymphoma cells |
| Q36811913 | Differences in the basal activity of the long terminal repeat determine different replicative capacities of two closely related human immunodeficiency virus type 1 isolates |
| Q36650675 | Differential contribution of herpes simplex virus type 1 gene products and cellular factors to the activation of human immunodeficiency virus type 1 provirus. |
| Q40041542 | Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants |
| Q44083711 | Distinct DNA targets for trans-activation by HTLV-1 tax and adenovirus E1A |
| Q35878102 | Distinct domains of adenovirus E1A interact with specific cellular factors to differentially modulate human immunodeficiency virus transcription |
| Q40941999 | Dual activity of pyrrolidine dithiocarbamate on kappa B-dependent gene expression in U937 cells: I. Regulation by the phorbol ester TPA. |
| Q37670711 | E1A-dependent trans-activation of the c-fos promoter requires the TATAA sequence |
| Q30452167 | Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity |
| Q38925477 | Functional comparison of herpes simplex virus 1 (HSV-1) and HSV-2 ICP27 homologs reveals a role for ICP27 in virion release |
| Q40043461 | Functional dissection of the human spumaretrovirus transactivator identifies distinct classes of dominant-negative mutants. |
| Q39605657 | GLI-2 modulates retroviral gene expression |
| Q36803871 | Genetic evidence for two distinct transactivation functions of the herpes simplex virus alpha protein ICP27. |
| Q33819189 | Genetic variation and HIV-associated neurologic disease. |
| Q40584444 | HIV, 'an evolving species'. Roles of cellular activation and co-infections |
| Q34848465 | Herpes simplex virus ICP0 promotes both histone removal and acetylation on viral DNA during lytic infection |
| Q36829889 | Herpes simplex virus alpha protein ICP27 possesses separable positive and negative regulatory activities |
| Q40065340 | Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells |
| Q24657245 | Herpes simplex virus type 1 immediate-early protein ICP27 is required for efficient incorporation of ICP0 and ICP4 into virions |
| Q36698102 | Herpes simplex virus type 1-mediated induction of human immunodeficiency virus type 1 provirus correlates with binding of nuclear proteins to the NF-kappa B enhancer and leader sequence |
| Q24675640 | Herpes simplex virus-infected cell protein 0 blocks the silencing of viral DNA by dissociating histone deacetylases from the CoREST-REST complex |
| Q44542182 | Herpesvirus quiescence in neuronal cells. V: forskolin-responsiveness of the herpes simplex virus type 1 alpha0 promoter and contribution of the putative cAMP response element |
| Q33850701 | Human GLI-2 is a tat activation response element-independent Tat cofactor |
| Q97567871 | Human Virus Transcriptional Regulators |
| Q36829008 | Human cytomegalovirus inhibits human immunodeficiency virus replication in cells productively infected by both viruses |
| Q33581303 | Human herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancer |
| Q24683663 | Human herpesvirus 6 |
| Q37572418 | Human immunodeficiency virus tat gene transfer to the murine central nervous system using a replication-defective herpes simplex virus vector stimulates transforming growth factor beta 1 gene expression |
| Q38345116 | Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation |
| Q39595632 | Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR |
| Q40065232 | Human immunodeficiency virus vectors for inducible expression of foreign genes |
| Q40266501 | ICP27-dependent resistance of herpes simplex virus type 1 to leptomycin B is associated with enhanced nuclear localization of ICP4 and ICP0. |
| Q36798152 | Identification of a transactivating function mapping to the putative immediate-early locus of human herpesvirus 6 |
| Q42644431 | Identification of an ICP27-responsive element in the coding region of a herpes simplex virus type 1 late gene |
| Q40308739 | Identification of dominant-negative mutants of the herpes simplex virus type 1 immediate-early protein ICP0 |
| Q30558705 | Immune adaptor ADAP in T cells regulates HIV-1 transcription and cell-cell viral spread via different co-receptors |
| Q36807211 | In vitro susceptibility of T lymphocytes from chimpanzees (Pan troglodytes) to human herpesvirus 6 (HHV-6): a potential animal model to study the interaction between HHV-6 and human immunodeficiency virus type 1 in vivo |
| Q33919346 | Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. |
| Q36698191 | Inducible transcriptional activation of the human immunodeficiency virus long terminal repeat by protein kinase inhibitors |
| Q26766356 | Infected cell protein 0 functional domains and their coordination in herpes simplex virus replication |
| Q40650845 | Infection with the intracellular protozoan parasite Theileria parva induces constitutively high levels of NF-kappa B in bovine T lymphocytes |
| Q37611462 | Inhibition by interferon of herpes simplex virus type 1-activated transcription of tat-defective provirus |
| Q35828854 | Inhibition of human immunodeficiency virus type 1 replication by a Tat-activated, transduced interferon gene: targeted expression to human immunodeficiency virus type 1-infected cells |
| Q40066650 | Inhibition of viral and cellular promoters by human wild-type p53 |
| Q28277712 | Interaction between c-Rel and the mitogen-activated protein kinase kinase kinase 1 signaling cascade in mediating kappaB enhancer activation |
| Q35876353 | Interaction of herpes simplex virus 1 alpha regulatory protein ICP0 with elongation factor 1delta: ICP0 affects translational machinery |
| Q39581386 | Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein |
| Q36405511 | Interactions between herpesviruses and retroviruses: Implications in the initiation of disease |
| Q39145175 | Interference of interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived macrophages |
| Q35828561 | Intracellular localization of the herpes simplex virus type 1 major transcriptional regulatory protein, ICP4, is affected by ICP27 |
| Q36688898 | Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeat |
| Q36057726 | Mammalian alphaherpesvirus miRNAs |
| Q38241249 | Mechanisms of viral-mediated trans-activation of transcription |
| Q35565668 | Modulation of NFAT-dependent gene expression by the RhoA signaling pathway in T cells |
| Q33753132 | Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review |
| Q40448842 | Multiple cooperative interactions constrain BPV-1 E2 dependent activation of transcription |
| Q36831514 | Multiple transcriptional regulatory domains in the human immunodeficiency virus type 1 long terminal repeat are involved in basal and E1A/E1B-induced promoter activity |
| Q40116979 | NF-kappa B-mediated activation of the human immunodeficiency virus enhancer: site of transcriptional initiation is independent of the TATA box. |
| Q24634681 | Pathogenesis of human immunodeficiency virus infection |
| Q28379107 | Pentoxifylline and other protein kinase C inhibitors down-regulate HIV-LTR NF-kappa B induced gene expression |
| Q33819612 | Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. |
| Q36638050 | Physical interaction between the herpes simplex virus type 1 immediate-early regulatory proteins ICP0 and ICP4. |
| Q34730830 | Poly(ADP-ribose) polymerase-1 is required for efficient HIV-1 integration |
| Q33809422 | Processing of alpha-globin and ICP0 mRNA in cells infected with herpes simplex virus type 1 ICP27 mutants |
| Q39195127 | Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. |
| Q44599513 | Pseudorabies virus early protein 0 trans-activates the TATA-associated promoter by stimulating the transcription initiation |
| Q34226294 | Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1 |
| Q36489392 | Reciprocal transactivation between HIV-1 and other human viruses |
| Q35990495 | Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: Potential role in blocking IFN-beta induction |
| Q41638947 | Regulation of gene expression directed by the long terminal repeat of the feline immunodeficiency virus |
| Q40756505 | Regulation of human immunodeficiency virus infection: implications for pathogenesis |
| Q35838772 | Repression in vitro, by human adenovirus E1A protein domains, of basal or Tat-activated transcription of the human immunodeficiency virus type 1 long terminal repeat |
| Q36793331 | Restricted expression of herpes simplex virus lytic genes during establishment of latent infection by thymidine kinase-negative mutant viruses |
| Q35667107 | Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1 |
| Q33889111 | Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector |
| Q33786060 | Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery |
| Q38318271 | Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides |
| Q38995600 | Seroepidemiological correlations of antibodies to human herpesviruses and human immunodeficiency virus type 1 in African patients |
| Q37694247 | Silencing of human immunodeficiency virus long terminal repeat expression by an adenovirus E1a mutant |
| Q41981808 | Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication |
| Q28340298 | Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine |
| Q38303578 | Synergistic activation of simian immunodeficiency virus and human immunodeficiency virus type 1 transcription by retinoic acid and phorbol ester through an NF-kappa B-independent mechanism |
| Q24644981 | Synergistic activation of the human immunodeficiency virus type 1 promoter by the viral Tat protein and cellular transcription factor Sp1 |
| Q36804236 | The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent. |
| Q36796351 | The Epstein-Barr virus BZLF1 gene product activates the human immunodeficiency virus type 1 5' long terminal repeat |
| Q36831819 | The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. |
| Q36653717 | The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICP0 during infection |
| Q45745359 | The TATA motif specifies the differential activation of minimal promoters by varicella zoster virus immediate-early regulatory protein IE62. |
| Q36649803 | The carboxy-terminal transcription enhancement region of the human spumaretrovirus transactivator contains discrete determinants of the activator function. |
| Q36626966 | The effects of cytomegalovirus on human immunodeficiency virus replication in brain-derived cells correlate with permissiveness of the cells for each virus |
| Q36827125 | The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes. |
| Q36655446 | The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency. |
| Q40066427 | The human cytomegalovirus 80-kilodalton but not the 72-kilodalton immediate-early protein transactivates heterologous promoters in a TATA box-dependent mechanism and interacts directly with TFIID. |
| Q40597354 | The human immunodeficiency virus type-1 long terminal repeat and its role in gene expression |
| Q38366893 | The immunopathogenesis of HIV infection |
| Q35816763 | The pathogenetic basis of viral tropism |
| Q28378673 | Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication |
| Q33666097 | Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein |
| Q33580416 | Trans-activation of the human immunodeficiency virus long terminal repeat sequences, expressed in an adenovirus vector, by the adenovirus E1A 13S protein |
| Q39996395 | Transactivation of a viral target gene by herpes simplex virus ICP27 is posttranscriptional and does not require the endogenous promoter or polyadenylation site |
| Q45788217 | Transactivation of human T-cell leukemia virus type 1 by herpes simplex virus type 1 |
| Q36693219 | Transactivation of the human immunodeficiency virus promoter by human herpesvirus 6 (HHV-6) strains GS and Z-29 in primary human T lymphocytes and identification of transactivating HHV-6(GS) gene fragments |
| Q36656119 | Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16 |
| Q37113939 | Transcriptional and Transforming Activities of the Adenovirus E1A Proteins |
| Q35852823 | Transcriptional transactivation of parvovirus B19 promoters in nonpermissive human cells by adenovirus type 2 |
| Q29618096 | Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B |
| Q44444269 | alpha-Lipoic acid: a metabolic antioxidant which regulates NF-kappa B signal transduction and protects against oxidative injury |
| Q36808930 | cis-acting elements in the U3 region of a simian immunodeficiency virus |
Search more.